A Phase Ib/II study of Venetoclax, IBERdomide and dexamethasone for patients in first or second relapse of Multiple myeloma and/or systemic AL amyloidosis with t(11;14)

What is the drug in question?

Iberdomide is a “CelMod”, which is similar to lenalidomide and pomalidomide. It is well tolerated with proven activity in myeloma. It is hoped that iberdomide to be more effective and less toxic than lenalidomide in the treatment of AL amyloidosis.

Venetoclax, a BCL2 inhibitor, which used in many haematological conditions, but in myeloma and AL amyloidosis, venetoclax specifically targets the effects of t(11;14) mutation.

Sites